secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001654954-25-009510
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics reports Q2 net loss of $10.9M; Phase 3 LEVEL study enrollment on track for H1 2026
--------------------------------------------------------------------------------

- Net loss of $10.9M in Q2 2025 vs $3.6M in Q2 2024; R&D spend $6.1M, G&A $5.7M.
- Cash and equivalents of $105.5M as of June 30, 2025, expected to fund operations through 2027.
- Phase 3 LEVEL study (TNX-103) enrollment target of 230 patients; completion expected H1 2026, topline data H2 2026.
- On track to initiate second Phase 3 study, LEVEL-2, in 2025 with over 85 sites in 15 countries qualified.
- Canadian patent allowed for TNX-103/102/101 and metabolites in PH-HFpEF, extending protection to 2040.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495425009510/0001654954-25-009510-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495425009510/tennx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-25-009510

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer